423 related articles for article (PubMed ID: 25445466)
1. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
2. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
3. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
[TBL] [Abstract][Full Text] [Related]
4. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
6. New agents in chronic lymphocytic leukemia.
Lin TS
Curr Hematol Malig Rep; 2010 Jan; 5(1):29-34. PubMed ID: 20425394
[TBL] [Abstract][Full Text] [Related]
7. Current strategies to create tailored and risk-adapted therapies for CLL patients.
Cramer P; Eichhorst B; Reinhardt HC; Hallek M
Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
[TBL] [Abstract][Full Text] [Related]
8. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for anti-CD20 antibodies in CLL?
Shah HR; Stephens DM
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
12. Possible novel agents in marginal zone lymphoma.
Zinzani PL; Broccoli A
Best Pract Res Clin Haematol; 2017; 30(1-2):149-157. PubMed ID: 28288710
[TBL] [Abstract][Full Text] [Related]
13. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
14. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
15. How should we sequence and combine novel therapies in CLL?
Davids MS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
[TBL] [Abstract][Full Text] [Related]
16. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
[TBL] [Abstract][Full Text] [Related]
17. Novel agents for the treatment of chronic lymphocytic leukemia.
Abou-Nassar K; Brown JR
Clin Adv Hematol Oncol; 2010 Dec; 8(12):886-95. PubMed ID: 21326166
[TBL] [Abstract][Full Text] [Related]
18. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
19. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT
Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963
[TBL] [Abstract][Full Text] [Related]
20. Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Woyach JA
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):476-481. PubMed ID: 31808904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]